Mirum Pharmaceuticals reported Q3 2026 net product sales of about US$186 million, lifted its full year sales guidance, and highlighted strong demand for LIVMARLI, bile acid medicines, and the initial U.S. launch of ATEBRIOZ following FDA approval for fibrodysplasia ossificans progressiva. Alongside the commercial update, Mirum outlined progress across rare disease programs, including ATEBRIOZ expansion in younger FOP patients and continued work on maralixibat and other Progressive Familial...
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FOSTER CITY, Calif., October 21, 2026--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-10-12. The following slide deck was published by Mirum Pharmaceuticals, Inc.
Mirum Pharma’s phase 3 EXPAND trial shows Livmarli eased cholestatic pruritus and cut bile acids. Read more here.
Mirum stock surges after LIVMARLI wins Phase 3 trial, showing significant itch and bile acid reduction in biliary atresia patients.
Mirum Pharma (MIRM) reports Phase 3 EXPAND LIVMARLI topline results Oct 12.
Detailed price information for Helus Pharma Inc (HELP-Q) from The Globe and Mail including charting and trades.
Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile. The company
Detailed price information for Kodiak Sciences Inc (KOD-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.